Registered title, quoted from ClinicalTrials.gov
FMD and Neoadjuvant Chemo-immunotherapy in TNBC
An open trial on breast cancer, registered on ClinicalTrials.gov. Led by Sun Yat-sen University Cancer Center; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07378306, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to 70 years; sex: women only
Registered eligibility fields
Documented evidence (pathological or radiological) of distant metastasis prior to treatment initiation.
Exclusion criterion 3
ECOG performance status score of 0 to 1, with an expected survival of >12 weeks.
Inclusion criterion 4
Hemoglobin ≥90 g/L (can be maintained or exceed this level via transfusion).
Inclusion criterion 9
Absolute neutrophil count ≥1.5 × 10E9/L.
Inclusion criterion 10
Platelet count ≥100 × 10E9/L.
Inclusion criterion 11
Total bilirubin ≤1.5 × upper limit of normal (ULN).
Inclusion criterion 12
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 × ULN.
Inclusion criterion 13
Creatinine ≤1.5 × ULN.
Inclusion criterion 14
Known infection with Human Immunodeficiency Virus (HIV).
Exclusion criterion 15
Female patients of childbearing potential must agree to use reliable methods of contraception from before trial entry, throughout the study, and for 8 weeks after the completion of the study.
Inclusion criterion 5
Pregnancy must be ruled out for women of childbearing potential (aged 15-49).
Inclusion criterion 16
Pregnant or lactating women.
Exclusion criterion 17
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07378306, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Written informed consent obtained from the patient or their legal representative.
- Good patient compliance, willing and able to adhere to the prescribed dietary intervention plan, visits, treatment schedule, laboratory tests, and other study procedures.
- Female, aged 18 to 70 years.
- ECOG performance status score of 0 to 1, with an expected survival of >12 weeks.
- Female patients of childbearing potential must agree to use reliable methods of contraception from before trial entry, throughout the study, and for 8 weeks after the completion of the study.
- Patients with pathologically confirmed primary breast cancer, with a primary tumor ≥2 cm and regional lymph node status N0-N3 (AJCC Version 8); patients with positive lymph nodes may have a primary tumor of any size; no distant metastases (M0).
- Triple-negative or near-triple-negative subtype, defined as HR-negative or low expression (ER and/or PR positivity rate 1%-10%) and HER2-negative (IHC 0, 1+, or 2+ with FISH-negative).
- No prior history of any anti-tumor therapy, including chemotherapy, radiotherapy, and biological therapy.
- Hemoglobin ≥90 g/L (can be maintained or exceed this level via transfusion).
- Absolute neutrophil count ≥1.5 × 10E9/L.
- Platelet count ≥100 × 10E9/L.
- Total bilirubin ≤1.5 × upper limit of normal (ULN).
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 × ULN.
- Creatinine ≤1.5 × ULN.
- Fasting blood glucose <250 mg/dL (13.89 mmol/L).
- Pregnancy must be ruled out for women of childbearing potential (aged 15-49).
Exclusion Criteria:
- Previous administration of any systemic anti-cancer therapy, including cytotoxic chemotherapy, targeted therapy, immunotherapy, or investigational treatment.
- Prior radiotherapy for breast cancer.
- Documented evidence (pathological or radiological) of distant metastasis prior to treatment initiation.
- History of another malignancy within the five years preceding treatment initiation in this study, except for carcinoma in situ of the cervix, cured basal cell carcinoma, or urothelial tumors of the bladder (including Ta and Tis).
- Known allergy or hypersensitivity to any component of the investigational drugs or products.
- Active autoimmune disease requiring systemic treatment (e.g., systemic lupus erythematosus, psoriasis, etc.).
- Body Mass Index (BMI) < 19 kg/m².
- Unintentional weight loss ≥5% within the past 3 months, unless the patient's BMI >22 kg/m² and weight loss at study entry is <10%; or unintentional weight loss ≥10% within the past 3 months, unless the patient's BMI >25 kg/m² and weight loss at study entry is <15%. In either case, weight must have been stable for at least one month prior to enrollment.
- Eating disorders, including anorexia nervosa, bulimia nervosa, etc.
- Baseline fasting blood glucose ≤60 mg/dL (3.33 mmol/L).
- Severe infection within 4 weeks prior to enrollment, including but not limited to hospitalization for infectious complications, bacteremia, or severe pneumonia.
- Type 1 or Type 2 diabetes mellitus requiring medication (including but not limited to insulin or insulin secretagogues), with the exception of metformin.
- Any unstable systemic disease, including: uncontrolled hypertension, unstable angina, angina pectoris with onset within the last 3 months, congestive heart failure, myocardial infarction (within 6 months prior to enrollment).
- Severe arrhythmia requiring medication, or significant hepatic, renal, or metabolic disease.
- Known infection with Human Immunodeficiency Virus (HIV).
- Active, uncontrolled hepatitis B or hepatitis C.
- Pregnant or lactating women.
- History of diagnosed neurological or psychiatric disorders, including epilepsy or dementia.
- Any other condition deemed by the investigator as unsuitable for participation.
Quoted from ClinicalTrials.gov, NCT07378306, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07378306, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.